Recent advancements in RNA research highlight the critical role of RNA modifications, particularly N6-methyladenosine (m6A), in gene regulation and disease progression. These modifications, which influence mRNA stability and translation, are now recognized as pivotal in understanding complex biological processes, including cancer and neurological disorders. However, capturing the abundance and precise locations of these modifications has been challenging, particularly with traditional methods that require high RNA inputs and lack comprehensive normalization strategies.
The introduction of AlidaBio’s EpiPlex™ Platform addresses these limitations by enabling accurate quantification of RNA modifications, even from ultra-low input samples. This innovative assay combines specific enrichment techniques with proximity barcoding chemistry to achieve high-resolution profiling of m6A and inosine. By facilitating the analysis of RNA methylation dynamics in various biological contexts, the EpiPlex Platform not only enhances the understanding of gene regulation but also opens new avenues for therapeutic development, particularly in oncology.
Start your 7-day trial and see what the database can do →
